2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
This guideline cites 19 of the 199 landmark trials in our Cardiology register.
- Issued by
- ACC/
AHA - Year
- 2025
- Source
- Rao SV, O'Donoghue ML, et al. Circulation. 2025;151(13):e771–e862.doi 10.1161/CIR.0000000000001309
The 2025 guideline merges the separate US STEMI (2013) and NSTE-ACS (2014) documents into a single ACS pathway — the same consolidation the ESC made in 2023. Two divergences from the ESC are worth knowing. Lipids: the US committee works with an LDL-C threshold rather than a target, adding a non-statin agent when LDL-C stays ≥70 mg/dL on maximally tolerated statin (and calling further intensification reasonable at 55–<70 mg/dL), where the ESC 2023 ACS guideline commits to a target of <55 mg/dL plus ≥50% reduction. Cardiogenic shock: with DanGer Shock in hand the microaxial flow pump becomes Class 2a in STEMI-related shock while the intra-aortic balloon pump and routine VA-ECMO are pushed down to Class 3 (no benefit) — the ESC document predates that trial. The register's ACS trials are grouped by theme below.
Antithrombotic & antiplatelet therapy7
- 2019ISAR-REACT 5Cardiology · Coronary · AntiplateletsIn 4,018 patients with acute coronary syndromes managed invasively, prasugrel reduced death, MI or stroke at one year compared with ticagrelor.HR 1.36Read →
- 2019AUGUSTUS CoreCardiology · Thrombosis · AF + PCIIn 4,614 patients with AF and recent ACS or PCI, apixaban without aspirin reduced major or clinically relevant bleeding compared with warfarin-based triple therapy.Read →
- 2013WOESTCardiology · Thrombosis · AF + PCIIn 573 patients on oral anticoagulation undergoing PCI, clopidogrel without aspirin reduced bleeding compared with triple therapy.HR 0.36Read →
- 2009PLATO CoreCardiology · Coronary · AntiplateletsIn 18,624 patients hospitalised with ACS, ticagrelor reduced CV death, MI or stroke compared with clopidogrel, with similar major bleeding.HR 0.84Read →
- 2007TRITON-TIMI 38Cardiology · Coronary · AntiplateletsIn 13,608 ACS patients undergoing planned PCI, prasugrel reduced ischaemic events but increased major bleeding relative to clopidogrel.HR 0.81Read →
- 2005COMMITCardiology · Coronary · clopidogrelIn 45,852 patients with acute myocardial infarction, clopidogrel added to aspirin reduced death, reinfarction, or stroke compared with placebo.9.2% vs 10.1%Read →
- 2001CURE CoreCardiology · Coronary · AntiplateletsIn 12,562 patients with NSTE-ACS, clopidogrel plus aspirin reduced the composite of CV death, MI or stroke versus aspirin alone.RR 0.8Read →
Reperfusion, invasive strategy & complete revascularisation3
- 2019COMPLETECardiology · Coronary · RevascularisationIn 4,041 STEMI patients with multivessel disease, staged complete revascularisation reduced CV death or MI compared with culprit-lesion-only PCI.HR 0.74Read →
- 2001TACTICS-TIMI 18Cardiology · Coronary · early invasive strategyIn 2,220 patients with NSTE-ACS treated with tirofiban, an early invasive strategy reduced 6-month death, MI, or rehospitalisation for ACS compared with a conservative strategy.OR 0.7895% CI 0.62-0.97Read →
- 1988ISIS-2 CoreCardiology · Coronary · ReperfusionIn 17,187 patients with suspected acute myocardial infarction, aspirin plus intravenous streptokinase reduced 5-week vascular mortality compared with placebo.8.0% vs 13.2%Read →
Cardiogenic shock & mechanical support2
- 2024DanGer ShockCardiology · Coronary · Cardiogenic shockIn 360 patients with STEMI-related cardiogenic shock, a microaxial flow pump (Impella CP) reduced 180-day all-cause mortality compared with standard care.HR 0.74Read →
- 2017CULPRIT-SHOCK CoreICU · CS / MCS · RevascularisationIn 706 patients with multivessel disease and cardiogenic shock, culprit-only PCI with staged completion reduced 30-day death or RRT compared with immediate multivessel PCI.RR 0.83Read →
Lipid-lowering & secondary prevention6
- 2023CLEAR OutcomesCardiology · Lipids · Non-statin LDLIn 13,970 statin-intolerant patients, bempedoic acid reduced major adverse cardiovascular events compared with placebo.HR 0.87Read →
- 2018ODYSSEY OUTCOMESCardiology · Lipids · PCSK9 inhibitorIn 18,924 patients with recent acute coronary syndrome on high-intensity statin, alirocumab reduced major adverse cardiovascular events compared with placebo (HR 0.85, 95% CI 0.78-0.93).HR 0.8595% CI 0.78-0.93Read →
- 2017FOURIERCardiology · Lipids · PCSK9iIn 27,564 patients with ASCVD on statins, evolocumab reduced CV death, MI, stroke, hosp UA or revasc compared with placebo.HR 0.8595% CI 0.79-0.92Read →
- 2017COMPASSCardiology · Thrombosis · Chronic atherosclerosisIn 27,395 patients with stable coronary or peripheral artery disease, low-dose rivaroxaban plus aspirin reduced cardiovascular death, stroke or MI compared with aspirin alone.HR 0.76Read →
- 2015IMPROVE-ITCardiology · Lipids · Non-statin LDLIn 18,144 patients post-ACS, ezetimibe added to simvastatin further reduced CV death, MI, UA, revasc or stroke compared with simvastatin alone.HR 0.94Read →
- 2004PROVE-ITCardiology · Lipids · StatinsIn 4,162 patients after acute coronary syndrome, intensive atorvastatin 80 mg reduced death or major cardiovascular events compared with moderate pravastatin 40 mg (16% relative reduction, P=0.005).22.4% vs 26.3%Read →
Beta-blockers after myocardial infarction1
- 2024REDUCE-AMICardiology · Coronary · beta-blockerIn 5,020 patients after acute MI with preserved LVEF (≥50%), beta-blocker therapy did not reduce all-cause death or new MI compared with no beta-blocker.HR 0.9695% CI 0.79-1.16Read →
Published since the guideline1
- 2025REBOOTCardiology · Coronary · beta-blockerIn 8,505 patients after myocardial infarction with LVEF >40%, beta-blocker therapy did not reduce death, reinfarction, or HF hospitalisation compared with no beta-blocker.HR 1.0495% CI 0.89-1.22Read →
Cited landmark trials not yet in the register5
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2019TWILIGHT
Ticagrelor monotherapy after three months of dual antiplatelet therapy.
- 2021HOST-EXAM
Clopidogrel beat aspirin as long-term single antiplatelet therapy after PCI.
- 2013PRAMI
Preventive PCI of non-culprit lesions in STEMI (alongside register trial COMPLETE).
- 2012IABP-SHOCK II
Neutral intra-aortic balloon pump trial behind the Class 3 recommendation.
- 2017DETO2X-AMI
No benefit from routine supplemental oxygen in acute MI.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.